Lidbree (Lidocaine)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, which stops the initiation and propagation of nerve impulses. By stabilising the neuronal membrane, it prevents the transmission of pain signals from the uterine tissue, resulting in a rapid and reversible loss of sensation at the site of application.

The specific dose of Lidbree is determined by the prescribing clinician based on the type of procedure, patient characteristics, and clinical guidelines. Healthcare professionals calculate the appropriate volume and concentration to achieve effective anesthesia while minimising systemic exposure.

Safety data for intrauterine lidocaine during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified obstetrician after careful assessment.

To order Lidbree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Lidbree (lidocaine) offers a rapid onset and moderate duration of action, which is comparable to other amide‑type local anesthetics such as bupivacaine. Lidocaine generally has a lower risk of prolonged cardiac toxicity, but its duration may be shorter, making it suitable for brief procedures.

Lidbree should be stored at room temperature, below 25 °C, in its original container. Protect the solution from moisture, direct sunlight and extreme temperatures. Ensure the vial is sealed until use and discard any product that appears discoloured or contaminated.

Lidbree is administered directly into the uterine cavity by a qualified healthcare professional. The solution is typically injected through a catheter or syringe under aseptic conditions, with careful aspiration to avoid intravascular injection before delivering the anesthetic.

Serious risks include allergic reactions such as anaphylaxis, cardiovascular toxicity (arrhythmias, severe hypotension), seizures, methemoglobinemia, and respiratory depression. Immediate medical attention is required if any of these symptoms develop during or after administration.

Lidbree should be avoided in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe hepatic impairment, and individuals with significant cardiac conduction disorders unless specifically advised by a physician.